Skip to main content
. Author manuscript; available in PMC: 2021 Oct 12.
Published in final edited form as: Adv Drug Deliv Rev. 2020 Oct 12;160:19–35. doi: 10.1016/j.addr.2020.10.004

Figure 2.

Figure 2

Design strategies for lymphatic-targeting drug delivery systems. A) From the peripheral tissue interstitium, particles sized 10–100nm drain passively via lymphatic capillaries and are taken up via LN-resident DCs, while larger >200nm particles are transported to the LN via peripheral tissue-resident APCs. In addition to size, PEGylation and incorporation of targeting ligands can also enhance lymphatic uptake. B) Depot-forming materials promote peripheral tissue APC infiltration followed by migration to the LN. C) Particles incorporated with high endothelial (HEV)-targeting ligands can enter via the bloodstream. D) Leaky vasculature of LN tumors or metastases may allow particles to enter from the bloodstream.